- Q4 reported results include 22 percent sales growth and EPS of $.78 - Q4 pro forma adjusted results include 16 percent sales growth and EPS of
$.90 - Full-year results highlighted by double-digit growth in both sales and
INDIANAPOLIS, Jan. 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2007.
Throughout this release, financial results are presented on both a
reported and a pro forma adjusted basis. Reported results were prepared in
accordance with generally accepted accounting principles (GAAP) and include
all sales and expenses recognized by the company during the period. Pro
forma adjusted results exclude items described in the reconciliation tables
below and also assume the ICOS acquisition was completed January 1, 2006.
The pro forma adjusted results are presented in order to provide additional
insights into the underlying trends in the business. Financial guidance is
also provided on both a reported and a pro forma adjusted basis.
Fourth-Quarter Highlights - Reported Results
-- Sales increased 22 percent, to $5.190 billion.
-- Products launched this decade -- Alimta(R), Byetta(R), Cialis(R),
Cymbalta(R), Forteo(R), Strattera(R), Symbyax(R), Xigris(R) and
Yentreve(R) -- collectively grew 55 percent, to $1.7 billion, and
accounted for 33 percent of total sales, compared with 26 percent of
total sales in the fourth quarter of 2006.
-- Net income and earnings per share grew to $854.4 million and $.78,
respectively, compared with fourth-quarter 2006 net income of $132.3'/>"/>
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved